Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 3 save search
SpringWorks Therapeutics Announces Nirogacestat Achieved Primary and All Key Secondary Endpoints in Phase 3 DeFi Trial in Adult Patients with Progressing Desmoid Tumors
Published: 2022-05-24 (Crawled : 12:00) - biospace.com/
SWTX | $42.48 -3.7% -3.84% 810K
|
Health Technology
|
| O: -2.45%
H: 2.51%
C: -10.09%
trial therapeutics phase 3
Alnylam Presents New Results from the ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1
Published: 2022-05-24 (Crawled : 12:00) - biospace.com/
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 1.04%
H: 1.53%
C: 1.37%
ALNY | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: -3.53%
H: 0.0%
C: -1.2%
results phase 3
Aldeyra Therapeutics Designates Schirmer Test as Sole Primary Endpoint in Phase 3 TRANQUILITY-2 Trial of Reproxalap in Dry Eye Disease
Published: 2022-05-24 (Crawled : 12:00) - biospace.com/
ALDX 4 | $3.99 0.5% 0.5% 430K
|
Health Technology
|
| O: -1.05%
H: 0.0%
C: -4.95%
disease test eye trial therapeutics designation phase 3 reproxalap
Aerie Pharmaceuticals Announces First Participant Dosed in the Phase 3 Registrational COMET-2 Study of AR-15512 for the Treatment of Dry Eye Disease
Published: 2022-05-24 (Crawled : 12:00) - biospace.com/
AERI | $15.25 0.0%
|
Health Technology
|
| O: -4.82%
H: 1.71%
C: -7.63%
ar-1551 treatment disease eye phase 3
Fifty Percent of Patients with Ulcerative Colitis Treated with Mirikizumab Achieved Clinical Remission at One Year in Lilly's Pivotal Phase 3 Study
Published: 2022-05-24 (Crawled : 08:00) - prnewswire.com
LLY | News | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 1.29%
H: 1.3%
C: 0.74%
year one phase 3 ulcerative colitis
AbbVie Presents Positive Data from Phase 3 Study of Cariprazine (VRAYLAR®) for the Adjunctive Treatment of Major Depressive Disorder at 2022 APA Annual Meeting
Published: 2022-05-23 (Crawled : 16:00) - biospace.com/
ABBV | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: -0.51%
H: 0.0%
C: 0.0%
vraylar treatment positive phase 3 major depressive disorder
Positive Results from VISEN’s Phase 3 Trial of Once-Weekly TransCon hGH in China Consistent with Ascendis Pharma’s Phase 3 Height Trial
Published: 2022-05-23 (Crawled : 15:00) - biospace.com/
ASND | $140.98 -0.84% -0.84% 220K
|
Health Technology
|
| O: 4.07%
H: 2.7%
C: 1.55%
trial china positive results phase 3
Alnylam Presents New 18-Month Results from Exploratory Cardiac Endpoints in HELIOS-A Phase 3 Study of Investigational Vutrisiran
Published: 2022-05-23 (Crawled : 12:00) - biospace.com/
ALNY | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: 2.06%
H: 0.0%
C: 0.0%
cardiac results phase 3
Concert Pharmaceuticals Reports Positive Topline Results for First CTP-543 Phase 3 Clinical Trial in Alopecia Areata
Published: 2022-05-23 (Crawled : 12:00) - biospace.com/
CNCE | $8.37 0.36% 0
|
Health Technology
|
| O: 6.07%
H: 8.26%
C: -13.24%
ctp-543 topline trial positive phase 3
Biohaven Provides Update on Phase 3 Clinical Trial Evaluating Troriluzole for Spinocerebellar Ataxia (SCA)
Published: 2022-05-23 (Crawled : 12:00) - biospace.com/
BHVN | News 0 d | $42.16 -4.25% 0.85% 3.7M
|
Health Technology
|
| O: 0.25%
H: 1.91%
C: 0.92%
trial phase 3
PolyPid Announces Recommendation by Data Safety Monitoring Board to Conclude Enrollment of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ at the Minimum Number of Patients Targeted Following Unblinded Interim Efficacy Analysis
Published: 2022-05-23 (Crawled : 12:00) - biospace.com/
PYPD | $4.3 -3.15% -3.26% 5.2K
|
Health Technology
|
| O: 2.54%
H: 4.77%
C: -3.24%
trial enroll phase 3
VISEN Pharmaceuticals Announces Top-line Results of Phase 3 Trial of Once-Weekly Lonapegsomatropin, Demonstrating Superior Efficacy, Comparable Safety and Tolerability to Daily Growth Hormone
Published: 2022-05-23 (Crawled : 08:00) - prnewswire.com
ASND | $140.98 -0.84% -0.84% 220K
|
Health Technology
|
| O: 4.07%
H: 2.7%
C: 1.55%
trial results growth hormone phase 3 topline
Positive Phase 3 study with aprocitentan demonstrates significant antihypertensive efficacy in patients with resistant hypertension
Published: 2022-05-23 (Crawled : 06:00) - globenewswire.com
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: 1.57%
H: 0.0%
C: 0.0%
hypertension positive phase 3
Menarini Group and Radius Health, Inc. announce publication of elacestrant pivotal Phase 3 EMERALD clinical trial data in the Journal of Clinical Oncology
Published: 2022-05-19 (Crawled : 16:20) - ir.radiuspharm.com
RDUS | $18.72 2.74% 2.67% 280K
|
Health Technology
|
| O: -2.67%
H: 0.0%
C: 0.0%
elacestrant trial publication group phase 3 elascestrant
Evkeeza® (evinacumab) Phase 3 Trial Demonstrates 48% LDL-C Reduction in Children with Ultra-rare Form of High Cholesterol
Published: 2022-05-21 (Crawled : 12:20) - prnewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
| Email alert
Add to watchlist
REGN | $893.66 -0.84% -0.84% 450K
|
Health Technology
| Email alert
Add to watchlist
TEVJF | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
evkeeza children cholesterol trial phase 3 rare
Menarini Group and Radius Health, Inc. announce publication of elacestrant pivotal Phase 3 EMERALD clinical trial data in the Journal of Clinical Oncology
Published: 2022-05-20 (Crawled : 08:00) - prnewswire.com
RDUS | $18.72 2.74% 2.67% 280K
|
Health Technology
|
| O: -2.67%
H: 0.0%
C: 0.0%
elacestrant trial publication group phase 3 elascestrant
Krystal Biotech to Present Additional Data on B-VEC from the GEM-3 Phase 3 Study at the Society for Investigative Dermatology Annual Meeting
Published: 2022-05-19 (Crawled : 00:00) - globenewswire.com
KRYS | $164.04 -3.3% -3.41% 280K
|
Health Technology
|
| O: 3.63%
H: 1.97%
C: 1.39%
biotech phase 3
Ocuphire Announces Positive Topline Results from LYNX-1 Phase 3 Trial Evaluating Nyxol® Eye Drops for Night Vision Disturbances
Published: 2022-05-19 (Crawled : 12:00) - biospace.com/
OCUP | $1.675 -3.74% -3.88% 240K
|
Health Technology
|
| O: -15.14%
H: 13.51%
C: 10.27%
nyxol topline eye trial positive phase 3
Zealand Pharma Announces Positive Results from Phase 3 Trial of Dasiglucagon in Pediatric Patients with Congenital Hyperinsulinism (CHI)
Published: 2022-05-19 (Crawled : 12:00) - globenewswire.com
ZEAL | $17.59 1.21% -4.21%
|
Health Technology
|
| O: 18.8%
H: 2.81%
C: -0.79%
pharma trial positive results phase 3
Aldeyra Therapeutics Announces that Post-Hoc Analysis of Phase 3 TRANQUILITY Trial Digital Photography Demonstrated Statistical Significance in Favor of Reproxalap Over Vehicle for Primary Endpoint of Ocular Redness
Published: 2022-05-18 (Crawled : 13:00) - biospace.com/
ALDX 4 | $3.99 0.5% 0.5% 430K
|
Health Technology
|
| O: 2.14%
H: 0.0%
C: -6.11%
ocular trial therapeutics phase 3 reproxalap
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.